In last trading session, NeuroSense Therapeutics Ltd (NASDAQ:NRSN) saw 0.38 million shares changing hands with its beta currently measuring -0.45. Company’s recent per share price level of $0.53 trading at $0.02 or 3.31% at ring of the bell on the day assigns it a market valuation of $7.23M. That closing price of NRSN’s stock is at a discount of -449.06% from its 52-week high price of $2.91 and is indicating a premium of 24.53% from its 52-week low price of $0.40. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.41 million shares which gives us an average trading volume of 215.69K if we extend that period to 3-months.
For NeuroSense Therapeutics Ltd (NRSN), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.24 in the current quarter.
NeuroSense Therapeutics Ltd (NASDAQ:NRSN) trade information
Upright in the green during last session for gaining 3.31%, in the last five days NRSN remained trading in the green while hitting it’s week-highest on Monday, 11/13/23 when the stock touched $0.53 price level, adding 7.02% to its value on the day. NeuroSense Therapeutics Ltd’s shares saw a change of -56.48% in year-to-date performance and have moved 7.16% in past 5-day. NeuroSense Therapeutics Ltd (NASDAQ:NRSN) showed a performance of -1.70% in past 30-days. Number of shares sold short was 0.12 million shares which calculate 0.3 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $5.25 to the stock, which implies a rise of 89.9% to its current value. Analysts have been projecting $3.00 as a low price target for the stock while placing it at a high target of $7.50. It follows that stock’s current price would drop -1315.09% in reaching the projected high whereas dropping to the targeted low would mean a loss of -466.04% for stock’s current value.
NeuroSense Therapeutics Ltd is more likely to be releasing its next quarterly report between November 25 and November 29 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
NeuroSense Therapeutics Ltd (NASDAQ:NRSN)’s Major holders
Insiders are in possession of 36.88% of company’s total shares while institution are holding 0.94 percent of that, with stock having share float percentage of 1.50%. Investors also watch the number of corporate investors in a company very closely, which is 0.94% institutions for NeuroSense Therapeutics Ltd that are currently holding shares of the company. Armistice Capital, LLC is the top institutional holder at NRSN for having 1.27 million shares of worth $1.89 million. And as of Jun 29, 2023, it was holding 9.29% of the company’s outstanding shares.
The second largest institutional holder is Point72 Asset Management, L.P., which was holding about 100000.0 shares on Jun 29, 2023. The number of shares represents firm’s hold over 0.73% of outstanding shares, having a total worth of $0.15 million.